IL-10 is a major mediator of sepsis-induced impairment in lung antibacterial host defense

Journal of Immunology

Volumn 162, Issue 1, 1999, Pages 392-399

  Steinhauser, Matthew L ^a   Hogaboam, Cory M ^a   Kunkel, Steven L ^a   Lukacs, Nicholas W ^a   Strieter, Robert M ^a   Standiford, Theodore J ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 10;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTEREMIA; BACTERIAL IMMUNITY; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; HOST RESISTANCE; LUNG ALVEOLUS MACROPHAGE; LUNG CLEARANCE; MOUSE; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SEPSIS;

ABDOMEN; ANIMALS; CECUM; CELL MOVEMENT; CYTOKINES; DISEASE MODELS, ANIMAL; FEMALE; IMMUNE SERA; IMMUNITY, NATURAL; INJECTIONS, INTRAPERITONEAL; INTERLEUKIN-10; INTUBATION, INTRATRACHEAL; LIGATION; LUNG; MICE; NEUTROPHILS; PHAGOCYTOSIS; PNEUMONIA, BACTERIAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; PUNCTURES; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 0032933560     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Bone, R. C., R. A. Balk, F. B. Cerra, R. P. Dellinger, A. M. Fein, W. A. Knaus, R. M. H. Schein, and W. J. Sibbald. 1992. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest 101:1644.
2. Parrillo, J. E., M. M. Parker, C. Natanson, A. F. Suffredini, R. L. Danner, R. E. Cunnion, and F. P. Ognibene. 1990. Septic shock in humans. Advances in the understanding of pathogenesis, cardiovascular dysfunction, and therapy. Ann. Intern. Med. 113:227.
3. Walley, K. R., N. W. Lukacs, T. J. Standiford, R. M. Strieter, and S. L. Kunkel. 1996. Balance of inflammatory cytokines related to severity and mortality of murine sepsis. Infect. Immun. 64:4733.
4. Randow, F., U. Syrbe, C. Meisel, D. Krausch, H. Zuckermann, C. Platzer, and H. D. Volk. 1995. Mechanism of endotoxin desensitization: involvement of interleukin 10 and transforming growth factor β. J. Exp. Med. 181:1887.
5. Volk, H. D., P. Reinke, D. Krausch, H. Zuckermann, K. Asadullah, J. M. Muller, W. D. Docke, and W. J. Kox. 1996. Monocyte deactivation: rationale for a new therapeutic strategy in sepsis. Intensive Care Med. 22:S474.
6. Faist, E., A. Markewitz, D. Fuchs, S. Lang, S. Zarius, F. W. Schildberg, H. Wachter, and B. Reichart. 1991. Immunomodulatory therapy with thymopentin and indomethacin. Ann. Surg. 214:264.
7. Docke, W. D., F. Randow, U. Syrbe, D. Krausch, K. Asadullah, P. Reinke, H. D. Volk, and W. Kox. 1997. Monocyte deactivation in septic patients: restoration by IFN-γ treatment. Nat. Med. 3:678.
8. Munoz, C., J. Carlet, C. Fitting, B. Misset, J. P. Bleroit, and J. M. Cavaillon. 1991. Dysregulation of in vitro cytokine production by monocytes during sepsis. J. Clin. Invest. 88:1747.
9. Wakefield, C. H., P. D. Cary, S. Foulds, J. R. T. Monson, and P. J. Guillou. 1993. Changes in major histocompatibilily complex class II expression in monocytes and T cells of patients developing infection after surgery. Br. J. Surg. 80:205.
10. Christou, N. V. 1985. Host-defense mechanisms in surgical patients: a correlative study of the delayed hypersensitivity skin-test response, granulocyte function and sepsis. Can. J. Surg. 28:39.
11. Appel, S. H., S. R. Wellhausen, R. Montgomery, R. C. DeWeese, and H. C. Polk. 1989. Experimental and clinical significance of endotoxin-dependent HLA-DR expression on monocytes. J. Surg. Res. 47:39.
12. Brun-Buisson, C., F. Doyon, J. Carlet, P. Dellamonica, F. Gouin, A. Leptoutre, J. C. Mercier, G. Offenstadt, and B. Regnier. 1995. Incidence, risk factors, and outcome of severe sepsis and septic shock in adults. JAMA 274:968.
13. Seidenfeld, J. J., D. F. Pohl, and R. D. Bell. 1986. Incidence, site and outcome of infections in patients with the adult respiratory distress syndrome. Am. Rev. Respir. Dis. 134:12.
14. Montgomery, A. B., M. A. Stager, and C. J. Carrico. 1985. Causes of mortality in patients with the adult respiratory distress syndrome. Am. Rev. Respir. Dis. 132:485.
15. Howard, M., T. Muchamuel, S. Andrade, and S. Menon. 1993. Interleukin 10 protects mice from lethal endotoxemia. J. Exp. Med. 177:1205.
16. Standiford, T. J., R. M. Strieter, N. W. Lukacs, and S. L. Kunkel. 1995. Neutralization of IL-10 increases lethality in endotoxemia: cooperative effects of macrophage inflammatory protein-2 and tumor necrosis factor. J. Immunol. 155: 2222.
17. Gerard, C., C. Bruyns, A. Marchant, D. Abramowicz, P. Vandenabeele, A. Delvaux, W. Fiers, M. Goldman, and T. Velu. 1993. Interleukin 10 reduces the release of tumor necrosis factor and prevents lethality in experimental endotoxemia. J. Exp. Med. 177:547.
18. Greenberger, M., R. M. Strieter, S. L. Kunkel, J. Danforth, R. Goodman, and T. J. Standiford. 1995. Neutralization of IL-10 increases survival in a murine model of Klebsiella pneumonia. J. Immunol. 155:722.
19. Van der Poll, T., A. Marchant, C. Keogh, M. Goldman, and S. Lowry. 1996. Interleukin-10 impairs host defense in murine pneumococcal pneumonia. J. Infect. Dis. 174:994.
20. Bermudez, L. E., and J. Champsi. 1993. Infection with Mycobacterium avium induces production of interleukin-10 (IL-10), and administration of anti-IL-10 antibody is associated with enhanced resistance to infection in mice. Infect. Immun. 61:3093.
21. Rolph, P., I. Nakainz, A. Sampson-Johannes, S. Fong, D. Lowe, H. Min, and L. In. 1992. IL-10, T lymphocyte inhibitor of human blood cell production of IL-10. J. Immunol. 148:808.
22. Kasama, T., R. M. Strieter, N. W. Lukacs, M. D. Burdick, and S. L. Kunkel. 1994. Regulation of neutrophil-derived chemokine expression by IL-10. J. Imnol. 152:3559.
23. Cassatella, M., L. Meda, S. Bonora, M. Ceska, and G. Constantin. 1993. Interleukin 10 (IL-10) inhibits the release of proinflammatory cytokines from human polymorphonuclear leukocytes: evidence for an autocrine role of tumor necrosis factor and IL-1β in mediating the production of IL-8 triggered by lipopolysaccharide. J. Exp. Med. 178:2207.
24. Laichalk, L. L., J. Danforth, and T. J. Standiford. 1996. Interleukin-10 inhibits neutrophil phagocytic and bactericidal activity. FEMS Immunol. Med. Microbiol. 15:181.
25. Oswald, I., T. Wynn, and A. Sher. 1992. Interleukin 10 inhibits macrophage microbicidal activity by blocking endogenous production of tumor necrosis factor α required as a costimulatory factor for interferon-γ-induced activation. Proc. Natl. Acad. Sci. USA 89:8676.
26. Howard, M., A. O'Garra, H. Ishida, R. Malefyt, and J. De Vries. 1992. Biological properties of interleukin 10. J. Clin. Immunol. 12:239.
27. O'Sullivan, S. T., J. A. Lederer, A. F. Horgan, D. H. L. Chin, J. A. Mannick, and M. L. Roderick. 1995. Major injury leads to predominance of the T helper-2 lymphocyte phenotype and diminished interleukin-12 production associated with decreased resistance. Ann. Surg. 4:482.
28. Ayala, A., Z. K. Deol, D. L. Lehman, C. D. Herdon, and I. H. Chaudry. 1994. Polymicrobial sepsis but not low-dose endotoxin infusion causes decreased splenocyte IL-2/IFN-γ release while increasing IL-4/IL-10 production. J. Surg. Res. 56:579.
29. Ayala, A., and I. H. Chaundry. 1996. Immune dysfunction in murine polymicrobial sepsis: mediators, macrophages, lymphocytes and apoptosis. Shock 6:S27.
30. Baker, C. C., I. H. Chaundry, H. O. Gaines, and A. E. Baue. 1983. Evaluation of factors affecting mortality rate after sepsis in a murine cecal ligation and puncture model. Surgery 94:331.
31. Goldblum, S. E., K. M. Wu, and M. Jay. 1985. Lung myeloperoxidase as a measure of pulmonary leukostasis in rabbits. J. Appl. Physiol. 59:1978.
32. Rouby, J., E. M. de Lassale, and P. Poete. 1992. Nosocomial bronchopneumonia in the critically ill: histologic and bacteriologic aspects. Am. Rev. Respir. Dis. 146:1059.
33. Dever, L. L., and W. G. Johanson. 1995. Pneumonia complicating adult respiratory distress syndrome. Clin. Chest Med. 16:147.
34. Niederman, M. S., and A. Fien. 1990. Sepsis syndrome, the adult respiratory distress syndrome, and nosocomial pneumonia: a common clinical sequence. Clin. Chest Med. 11:633.
35. Maloney, S. D. 1995. Epidemic nosocomial pneumonia in the intensive care unit. Clin. Chest Med. 16:209.
36. Broug-Holub, E., G. B. Toews, J. Freek van Iwaarden, R. M. Strieter, S. L. Kunkel, R. Paine III, and T. J. Standiford. 1997. Alveolar macrophages are required for protective pulmonary defenses in murine Klebsiella pneumonia: elimination of alveolar macrophages increases neutrophil recruitment but decreases bacterial clearance and survival. Infect. Immun. 65:1139.
37. Richardson, J. D., D. E. Fry, L. Van Arsdall, and L. M. Flint Jr. 1979. Delayed pulmonary clearance of gram-negative bacteria: the role of intraperitoneal sepsis. J. Surg. Res. 26:499.
38. Richardson, J. D., M. M. DeCamp, R. N. Garrison, and D. E. Fry. 1982. Pulmonary infection complicating intra-abdominal sepsis. Ann. Surg. 195:732.
39. Haas, J. G., P. A. Baeuerle, G. Riethmuller, and H. W. L. Ziegler-Heitbrock. 1990. Molecular mechanism in down-regulation of tumor necrosis factor expression. Proc. Natl. Acad. Sci. USA 87:9563.
40. 2 is a potent inhibitor of human interleukin 12 production. J. Exp. Med. 181:775.
41. 2. J. Exp. Med. 180: 2365.